Dr. Reddy’s Laboratories Limited (NYSE:RDY) shares traded higher over the last trading session, gaining 0.70% on 02/11/21. The shares fell to a low of $65.72 before closing at $66.18. Intraday shares traded counted 0.13 million, which was 27.23% higher than its 30-day average trading volume of 174.04K. RDY’s previous close was $65.72 while the outstanding shares total 165.86M. The firm has a beta of 0.43, a 12-month trailing P/E ratio of 52.32. The stock’s Relative Strength Index (RSI) is 48.40, with weekly volatility at 1.28% and ATR at 1.51. The RDY stock’s 52-week price range has touched low of $33.33 and a $73.50 high.
Investors have identified the Drug Manufacturers – Specialty & Generic company Dr. Reddy’s Laboratories Limited as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $10.73 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Dr. Reddy’s Laboratories Limited (RDY) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For RDY, the company has in raw cash 59.0 million on their books with 191.0 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 1.83 billion total, with 1.01 billion as their total liabilities.
Having a look at the company’s valuation, the company is expected to record 2.42 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on RDY sounds very interesting.
Is the stock of RDY attractive?
In the last 6 months, insiders have changed their ownership in shares of company stock by 27.70%.
24 out of 36 analysts covering the stock have rated it a Buy, while 6 have maintained a Hold recommendation on Dr. Reddy’s Laboratories Limited. 2 analysts has assigned a Sell rating on the RDY stock. The 12-month mean consensus price target for the company’s shares has been set at $72.50.